NCT05911295 2026-04-20
Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2
Seagen Inc.
Phase 3 Active not recruiting
Clinical Trials
25 trialsNCT03661320 2026-04-15
A Study to Compare Chemotherapy Alone Versus Chemotherapy Plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Therapy After Surgery With Nivolumab or Nivolumab and BMS-986205 in Participants With Muscle Invasive Bladder Cancer
Bristol-Myers Squibb
Phase 3 Active not recruiting
NCT03775265 2026-04-13
Chemoradiotherapy With or Without Atezolizumab in Treating Patients With Localized Muscle Invasive Bladder Cancer
National Cancer Institute (NCI)
Phase 3 Active not recruiting
NCT04658862 2026-04-13
SunRISe-2
Janssen Research & Development, LLC
Phase 3 Active not recruiting
NCT07097142 2026-04-08
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study
NRG Oncology
Phase 3 Recruiting
NCT06960577 2026-03-30
Perioperative Durvalumab With Neoadjuvant ddMVAC or Gemcitabine/Cisplatin in Patients With Muscle-invasive Bladder Cancer (NIAGARA-2)
AstraZeneca
Phase 3 Recruiting
NCT03732677 2026-03-13
NIAGARA
AstraZeneca
Phase 3 Active not recruiting
NCT04700124 2026-02-05
KEYNOTE-B15
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT03682068 2026-02-03
NILE
AstraZeneca
Phase 3 Active not recruiting
NCT03924856 2025-08-28
KEYNOTE-866
Merck Sharp & Dohme LLC
Phase 3 Active not recruiting
NCT04574960 2025-07-20
NAUTICAL
University Health Network, Toronto
Phase 3 Recruiting
NCT02807636 2025-02-24
IMvigor130
Hoffmann-La Roche
Phase 3 Completed
NCT06364904 2025-02-21
A Clinical Trail to Determine the Safety and Efficacy of the Combination of Tislelizumab With Cisplatin and Gemcitabine, With or Without Trilaciclib for Patients With Untreated Unresectable and Metastatic Urothelial Carcinoma.
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 3 Not yet recruiting
NCT04241185 2024-11-25
MK-3475-992
Merck Sharp & Dohme LLC
Phase 3 Active not recruiting
NCT00003376 2023-06-22
Two-Drug Combination Chemotherapy Compared With Four-Drug Combination Chemotherapy in Treating Patients With Advanced Cancer of the Urothelium
Eastern Cooperative Oncology Group
Phase 3 Completed
NCT00003701 2023-06-15
Combination Chemotherapy in Treating Patients With Bladder Cancer
Eastern Cooperative Oncology Group
Phase 3 Completed
NCT00330499 2017-07-12
Efficacy Study of Adding Chemotherapy to Radiotherapy for Treating Bladder Cancer.
Trans Tasman Radiation Oncology Group
Phase 3 Completed
NCT00005047 2017-06-08
4B951, Combination Chemotherapy in Treating Patients With Bladder Cancer
SWOG Cancer Research Network
Phase 3 Terminated
NCT00028756 2016-08-02
Comparison of Immediate and Delayed Adjuvant Chemotherapy in Treating Patients Who Have Undergone a Radical Cystectomy for Stage III or Stage IV Transitional Cell Carcinoma of the Bladder Urothelium
European Organisation for Research and Treatment of Cancer - EORTC
Phase 3 Completed
NCT00014534 2016-07-14
Combination Chemotherapy in Treating Patients With Bladder Cancer
Alliance for Clinical Trials in Oncology
Phase 3 Completed
NCT00625664 2016-05-05
CILAB
Sanofi
Phase 3 Completed
NCT02074189 2014-02-28
Adjuvant Chemotherapy Following Radical Cystectomy to Treat Locally Advanced Bladder Cancer
Southwest Hospital, China
Phase 3 Unknown
NCT00054626 2013-12-18
Cisplatin and Gemcitabine Compared With Observation in Treating Patients Who Have Undergone Surgery for Bladder Cancer
National Cancer Institute (NCI)
Phase 3 Unknown
NCT00022191 2013-06-12
Cisplatin Plus Gemcitabine With or Without Paclitaxel in Treating Patients With Stage IV Urinary Tract Cancer
European Organisation for Research and Treatment of Cancer - EORTC
Phase 3 Completed
NCT00237575 2012-05-23
Randomized Phase III Trial of Leukine® vs Neupogen® in Patients Receiving Cisplatin & Gemcitabine for Urothelial Cancer
University of Kentucky
Phase 3 Terminated